Several prognostic biomarkers are widely recognized for their role in various cancers. For example: - HER2/neu in breast cancer: Overexpression of this protein is associated with aggressive disease and poor prognosis. - KRAS mutations in colorectal cancer: Presence of these mutations often indicates resistance to certain therapies and poorer outcomes. - TP53 mutations: Found in many types of cancer, these mutations are linked to more aggressive disease and lower survival rates.
